scholarly journals Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On‐Demand HIV Preexposure Prophylaxis

2019 ◽  
Vol 107 (5) ◽  
pp. 1200-1208 ◽  
Author(s):  
Stephanie N. Liu ◽  
Brandon T. Gufford ◽  
Jessica Bo Li Lu ◽  
Lane R. Bushman ◽  
Peter L. Anderson ◽  
...  
Keyword(s):  
Tenofovir Disoproxil Fumarate ◽  
Inhibitory Effects ◽  
On Demand ◽  
Preexposure Prophylaxis

Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis

2020 ◽  
Vol 173 (6) ◽  
pp. 507-508
Author(s):  
Rochelle P. Walensky ◽  
Tim Horn ◽  
Nicole C. McCann ◽  
Kenneth A. Freedberg ◽  
A. David Paltiel
Keyword(s):  
Tenofovir Disoproxil Fumarate ◽  
Preexposure Prophylaxis ◽  
Tenofovir Alafenamide

scholarly journals Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine

2018 ◽  
Vol 67 (3) ◽  
pp. 411-419 ◽  
Author(s):  
David V Glidden ◽  
Kathleen Mulligan ◽  
Vanessa McMahan ◽  
Peter L Anderson ◽  
Juan Guanira ◽  
...  
Keyword(s):  
Tenofovir Disoproxil Fumarate ◽  
Metabolic Effects ◽  
Preexposure Prophylaxis

scholarly journals HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health

AIDS ◽  
2020 ◽  
Vol 34 (5) ◽  
pp. 699-706 ◽  
Author(s):  
Simon B. Ascher ◽  
Rebecca Scherzer ◽  
Michelle M. Estrella ◽  
Judy Shigenaga ◽  
Kimberly A. Spaulding ◽  
...  
Keyword(s):  
Kidney Function ◽  
Tenofovir Disoproxil Fumarate ◽  
Preexposure Prophylaxis

scholarly journals Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Jillian Pintye ◽  
Agnes Langat ◽  
Benson Singa ◽  
John Kinuthia ◽  
Beryne Odeny ◽  
...  
Keyword(s):  
Tenofovir Disoproxil Fumarate ◽  
Self Report ◽  
Linear Regression Models ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Growth Outcomes ◽  
Preexposure Prophylaxis ◽  
Hiv Exposed ◽  
Relationship Of ◽  
Exposed Uninfected

Background. Tenofovir disoproxil fumarate (TDF) is commonly used in antiretroviral treatment (ART) and preexposure prophylaxis regimens. We evaluated the relationship of prenatal TDF use and growth outcomes among Kenyan HIV-exposed uninfected (HEU) infants.Materials and Methods.We included PCR-confirmed HEU infants enrolled in a cross-sectional survey of mother-infant pairs conducted between July and December 2013 in Kenya. Maternal ART regimen during pregnancy was determined by self-report and clinic records. Six-week and 9-monthz-scores for weight-for-age (WAZ), weight-for-length (WLZ), length-for-age (LAZ), and head circumference-for-age (HCAZ) were compared among HEU infants with and without TDF exposure usingt-tests and multivariate linear regression models.Results.Among 277 mothers who received ART during pregnancy, 63% initiated ART before pregnancy, of which 89 (32%) used TDF. No differences in birth weight (3.0 kg versus 3.1 kg,p=0.21) or gestational age (38 weeks versus 38 weeks,p=0.16) were detected between TDF-exposed and TDF-unexposed infants. At 6 weeks, unadjusted mean WAZ was lower among TDF-exposed infants (−0.8 versus −0.4,p=0.03), with a trend towards association in adjusted analyses (p=0.06). There were no associations between prenatal TDF use and WLZ, LAZ, and HCAZ in 6-week or 9-month infant cohorts.Conclusion.Maternal TDF use did not adversely affect infant growth compared to other regimens.

scholarly journals Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis

2019 ◽  
Vol 70 (8) ◽  
pp. 1717-1724 ◽  
Author(s):  
Melanie R Nicol ◽  
Prosperity Eneh ◽  
Rita Nakalega ◽  
Thomas Kaiser ◽  
Samuel Kabwigu ◽  
...  
Keyword(s):  
Medroxyprogesterone Acetate ◽  
Tenofovir Disoproxil Fumarate ◽  
Genital Tract ◽  
Female Genital Tract ◽  
Depot Medroxyprogesterone Acetate ◽  
Preexposure Prophylaxis ◽  
Increased Risk ◽  
Vaginal Swabs ◽  
Tenofovir Diphosphate ◽  
Female Genital

Abstract Background Effective concentrations of antiretrovirals in the female genital tract (FGT) are critical for suppression of viral shedding or effective preexposure prophylaxis. The disposition of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in the FGT have been previously described. Despite widespread use, however, lamivudine triphosphate (3TC-TP) exposure in the FGT is unknown. Depot medroxyprogesterone acetate (DMPA) and vaginal dysbiosis have been implicated in increased risk of human immunodeficiency virus (HIV) acquisition, but whether they alter TFV-DP or 3TC-TP exposure, and therefore compromise prevention efficacy, is unknown. Methods Fifty premenopausal women living with HIV in Kampala, Uganda, and receiving daily tenofovir disoproxil fumarate/lamivudine were recruited. Ectocervical biopsies were obtained for quantification of TFV-DP and 3TC-TP using liquid chromatography–mass spectrometry. 16S ribosomal RNA gene sequencing was performed on DNA extracted from vaginal swabs. Wilcoxon rank-sum was used to test for differences between contraceptive groups. Results 3TC-TP concentrations were on average 17-fold greater than TFV-DP concentrations in cervical tissues. TFV-DP concentrations in cervical biopsies were 76% greater in DMPA users compared with women using nonhormonal contraception (n = 23 per group). Abundance of Lactobacillus in vaginal swabs was correlated with 3TC-TP concentrations in cervical tissues. Conclusions We found that TFV-DP concentrations were significantly greater in DMPA users compared with women using nonhormonal contraception, suggesting that prevention efficacy is unlikely to be compromised by DMPA use. Similar to reports of FTC-TP, 3TC-TP exposure was significantly greater than TFV-DP in cervical tissue and was correlated with abundance of Lactobacillus. These data support lamivudine as an option for preexposure prophylaxis. Clinical Trials Registration NCT03377608.

scholarly journals On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

2015 ◽  
Vol 373 (23) ◽  
pp. 2237-2246 ◽  
Author(s):  
Jean-Michel Molina ◽  
Catherine Capitant ◽  
Bruno Spire ◽  
Gilles Pialoux ◽  
Laurent Cotte ◽  
...  
Keyword(s):  
High Risk ◽  
On Demand ◽  
Preexposure Prophylaxis ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document